Shanghai De Novo Pharmatech announced achievement of important First-in-Human milestone in China in phase I Trials with the novel investigational STING agonist DN015089. This Phase Ia/Ib open-label, multi-center study is designed to investigate the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary antitumor activity of DN015089 monotherapy in Chinese patients with advanced solid tumors (CTR20212462).